Related Experiment Video
Updated: Aug 14, 2026
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma
Xiaosong Wang1, Haitao Zhao, Qingwen Xu
1Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100083, China.
Abstract:
Tumor-associated antigens (TAAs) have been the most actively employed targets in the clinical diagnosis and treatment of human carcinoma, such as PSA in the diagnosis of prostate cancer and NY-ESO-1 in the immunotherapy of melanoma and other cancers. However, identification of TAAs has often been hampered by the complicated and laborsome laboratory procedures. In order to accelerate the process of tumor antigen discovery, and thereby improve diagnosis and treatment of human carcinoma, we have made an effort to establish a publicly available Human Potential Tumor Associated Antigen database (HPtaa) with potential TAAs identified by in silico computing (http://www.hptaa.org). Tumor specificity was chosen as the core of tumor antigen evaluation, together with other relevant clues. Various platforms of gene expression, including microarray, expressed sequence tag and SAGE data, were processed and integrated by several penalty algorithms. A total of 3518 potential TAAs have been included in the database, which is freely available to academic users. As far as we know, this database is the first one addressing human potential TAAs, and the first one integrating various kinds of expression platforms for one purpose.
Insights
Researchers developed the Human Potential Tumor Associated Antigen database (HPtaa) to speed up the discovery of novel tumor antigens. This resource aids in improving cancer diagnosis and treatment by identifying potential tumor-associated antigens (TAAs).
Area of Science:
- Oncology
- Bioinformatics
- Genomics
Background:
- Tumor-associated antigens (TAAs) are crucial for cancer diagnosis and immunotherapy.
- Current methods for identifying TAAs are often complex and time-consuming.
- Accelerating TAA discovery can significantly improve cancer patient outcomes.
Purpose of the Study:
- To establish a publicly accessible database of potential human TAAs.
- To facilitate faster identification and validation of novel tumor antigens.
- To support advancements in cancer diagnostics and therapeutic strategies.
Main Methods:
- In silico computation was employed to identify potential TAAs.
- Tumor specificity was a primary criterion for antigen evaluation.
- Gene expression data from multiple platforms (microarray, EST, SAGE) were integrated using penalty algorithms.
Main Results:
- The Human Potential Tumor Associated Antigen database (HPtaa) was created, featuring 3518 potential TAAs.
- The database integrates diverse gene expression data sources.
- HPtaa is freely available for academic use.
Conclusions:
- HPtaa is the first database dedicated to human potential TAAs.
- This resource streamlines TAA discovery by integrating various expression data.
- The database is expected to accelerate research in cancer diagnostics and treatment.
